Versant Venture Management, LLC — Q2 2021 13F Holdings

Name: Versant Venture Management, LLC — 13F Holdings, Q2 2021
Creator: AlphaSMO
License: https://www.sec.gov/forms

CIK: 0001560009

Total reported value

$141.4M

Full holdings list this quarter

#	Ticker	Issuer	Asset Subclass	Weight	Weight Change	Shares Change
1	CRSP	CRISPR Therapeutics AG	Stock-Healthcare	27.28%	-0.16%	-67.29%
2	✓	Passage Bio INC	Stock-Other	21.76%	—	—
3	✓	Aligos Therapeutics INC	Stock-Other	15.67%	—	-29.52%
4	2JQ	Gritstone Bio INC	Stock-Other	13.46%	—	—
5	ADVMCHF	Adverum Biotechnologies INC	Stock-Other	5.88%	—	—
6	CRNX	Crinetics Pharmaceuticals In	Stock-Other	5.13%	—	-59.58%
7	AKRO	Akero Therapeutics INC	Stock-Other	5.08%	—	—
8	✓	Flexion Therapeutics INC	Stock-Other	2.73%	—	-23.67%
9	✓		Stock-Other	2.04%	—	—
10	CBAYUSD	Cymabay Therapeutics INC	Stock-Other	0.79%	—	—
11	CLVSEUR	Clovis Oncology INC	Stock-Other	0.20%	—	—

Position changes disclosed by Versant Venture Management, LLC for the quarter ending Q2 2021, including ticker, issuer, weight change, shares change, and action
#	Ticker	Issuer	Weight Change	Shares Change	Action
1	CRSP	CRISPR Therapeutics AG	—	EXIT	Sold out
2	✓	Passage Bio INC	—	EXIT	Sold out
3	✓	Aligos Therapeutics INC	—	EXIT	Sold out
4	ADVMCHF	Adverum Biotechnologies INC	—	EXIT	Sold out
5	2JQ	Gritstone Bio INC	—	EXIT	Sold out
6	CRNX	Crinetics Pharmaceuticals In	—	EXIT	Sold out
7	AKRO	Akero Therapeutics INC	—	EXIT	Sold out
8	✓	Flexion Therapeutics INC	—	EXIT	Sold out
9	✓		—	EXIT	Sold out
10	CBAYUSD	Cymabay Therapeutics INC	—	EXIT	Sold out
11	CLVSEUR	Clovis Oncology INC	—	EXIT	Sold out